Results of the High dose arm of the Phase I/II Mexico City Trial (2 shots at days 10 and 28 after doctor’s visit with symptoms).

After one year of observation, the AuRx therapy was found to completely block recurrent disease in 43.5% of the treated patients treated while only 13% of the placebo group were free of recurrences. 61% of the treated patients had 2 or less recurrences where they had experienced an average of 8.5 recurrences the previous year. The number of recurrent episodes relative to previous year was reduced 3 fold (P<0.001).

Overall, there was a 2 fold reduction in episodes/patient in treated vs. placebo group in a statistically significant result - an average of 2.52 episodes per treated patient vs 4.8 in the placebo group.

Results of the Low dose arm of the Phase I/II Mexico City Trial (3 shots at days 7, 17 and 28 after doctor’s visit with symptoms) after 6 months observation.

During the first six months after the inoculations, recurrences in the treated group were prevented completely in 37.5% of the patients, whereas in the placebo group, 100% of the patients had at least one recurrence. Treated patients had 50% fewer recurrences and this result was statistically significant. Itching, vesicles, pain, ulcers, painful urination, and burning in the genital area were also reduced significantly.